Bartolome-Nebreda, Jose Manuel et al. published their patent in 2018 |CAS: 1820711-82-7

The Article related to triazolopyrimidine preparation oga inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Related Products of 1820711-82-7

On August 30, 2018, Bartolome-Nebreda, Jose Manuel; Trabanco-Suarez, Andres Avelino; Alcazar-Vaca, Manuel Jesus published a patent.Related Products of 1820711-82-7 The title of the patent was [1,2,4]Triazolo[1,5-a]pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as OGA inhibitors and their preparation. And the patent contained the following:

The invention relates to compounds of formula I as O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising compounds of formula I, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer’s disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathol., in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations. Compounds of formula I wherein X1 and X3 are independently CRxa, N and NH and derivatives; X2 is CH; X4 is C and N; X5, X6, X7 and X8 are independently C, CRxb and N; with the proviso that at least one of X1 and X3 is N and NH and derivatives; Rxa and Rxb are independently H, halo, CN, (un)substituted C1-4 alkyl, etc.; La is a bond, CHR1, O and NR1; Ra is CHR1, O, NR1, (un)substituted piperidinyl, (un)substituted morpholinyl, etc.; R1 is H and (un)substituted C1-4 alkyl; dashed bonds are single and double bonds; and tautomers and stereoisomeric forms thereof, are claimed. Example compound II was prepared by N-sulfonylation of 7-((3R)-piperidin-3-yl)-[1,2,4]triazolo[1,5-a]pyrimidine with 2-acetylaminothiazole-5-sulfonyl chloride. The invention compounds were evaluated for their OGA inhibitory activity. From the assay, it was determined that compound II exhibited pIC50 value of 6.06 and Emax of 94.20 %. The experimental process involved the reaction of tert-Butyl 6-bromo-1H-pyrrolo[3,2-b]pyridine-1-carboxylate(cas: 1820711-82-7).Related Products of 1820711-82-7

The Article related to triazolopyrimidine preparation oga inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Related Products of 1820711-82-7

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem